Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

• Damien McDonald appointed CEO, effective as of May 12, 2025
• Company reiterates guidance for first quarter revenues and aEBITDA

WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million. 

Sharon Wienbar, Lead Independent Director at Enovis, stated, “On behalf of the Board, I am thrilled to welcome Damien to the Enovis team. The Board of Directors, with the assistance of a leading executive search firm, carefully identified, evaluated and interviewed highly qualified candidates and Damien stood out. His strong track record as CEO of a public, global medical technology combined with his long history of relevant business successes and his similar approach to business processes and culture make him the right leader for Enovis at this stage in our growth journey.”

Mr. McDonald joins Enovis with more than 35 years of experience in the medical device industry. Most recently, he served as CEO of LivaNova, a global business creating clinically differentiated medical devices for the head and heart to improve the lives of patients worldwide. In his six years there, he drove improved results in growth, profitability and shareholder value. He also made a meaningful impact on company culture, centered on a ‘Patients First’ mindset. Earlier in his career, he was a Group Executive and Corporate Vice President leading a $1.5 billion group of dental consumables companies at Danaher. Additionally, he previously led Zimmer’s spine division and global marketing for J&J’s Ethicon business unit.